1725 – Transanal total mesorectal excision for the treatment of rectal cancer and benign disease

Page last updated: 01 November 2022

Application Detail

Description of Medical Service

Transanal total mesorectal excision (TaTME) is a surgical technique primarily used in patients undergoing surgery to remove rectal cancer tumours. TaTME is used in patients with cancer located in the lower rectum, providing an alternative method of access to the low pelvis for dissection and reconstruction. Dissection is performed using both an abdominal approach (from above) and a transanal approach (from below), which eventually meet. It is also utilised in selected benign cases that would otherwise likely require a permanent stoma.

Description of Medical Condition

Rectal cancer arises from the lining of the rectum. The rectum is the last part of the large intestine, starting at the final segment of the colon and ending at the short, narrow passage leading to the anus.

Reason for Application

New MBS item

Medical Service Type

Therapeutic technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 959 KB)
Application Form (Word 56 KB)

Consultation Survey

Consultation Survey (PDF 658 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
PASC consultation closes 4 November 2022

MSAC Consultation
MSAC consultation TBA – please subscribe to the MSAC Email Bulletin to be notified when consultation opens for this application

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

8–9 December 2022

ESC

-

MSAC

-